TrialInternational journal of cancer2026

Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.

Jurek Hille et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.